Work

Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?

Year: 2023

Type: article

Study design: Observational Study

Source: Annals of Surgical Oncology

DOI: 10.1245/s10434-023-13935-0

Authors: Kristen E. Rhodin, Sin-Ho Jung, Kelly Elleson, Danielle DePalo, Richard Straker, Sophia McKinley, Kate Beekman, Lily Parker, Suephy Chen, Matthew K. Iyer, April K. S. Salama, Edmund Bartlett, Giorgos Karakousis, Jonathan S. Zager, Douglas S. Tyler, Georgia M. Beasley

Institutions: Duke University, Moffitt Cancer Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, The University of Texas Medical Branch at Galveston

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, Regeneron Pharmaceuticals, National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases

Awards: PVSRIPO in melanoma, Cancer Center Support Grant, Stimulating Access to Research in Residency (StARR) - NIAID, SPORE in Skin Cancer

OpenAlex ID: W4385073400

FWCI: 1.173

Cites: 32

Cited by: 10

Related to: 10